Cystic fibrosis cell models for high-throughput analysis and drug screening
Journal of Cystic Fibrosis · 2024
DOI: 10.1016/j.jcf.2024.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von Aidi Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, Rice University, Houston, Texas 77030, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, High-Throughput Screening Assays, Drug Evaluation, Preclinical. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Cancer Prevention and Research Institute of Texas, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
Cystic fibrosis (CF) is a single-gene disorder that affects the lung, digestive system, and other organs. Mutations in the CF transmembrane conductance regulator (CFTR) gene are classified into several classes based on their pathogenic mechanism and clinical severity. The distinct and heterogeneous clinical behavior of each CF class and the respective CFTR mutations have made the development of a durable therapy for all CF patients extremely challenging. While the FDA-approved drug elexacaftor/tezacaftor/ivacaftor (Trikafta) benefits CF patients carrying at least one F508del mutation in CFTR, it's not effective for many CF patients carrying a variety of other CFTR mutations. To establish a better understanding of CF pathophysiology and aid the development of novel therapeutics for different classes of CF patients, we have created four CF-mutation-specific cell models that recapitulate respectively four distinct CF classes and disease phenotypes, as confirmed by sequencing, CFTR mRNA and protein quantification. The channel function of each cell model was first validated using a well-established FLIPR (Fluorescent Imaging Plate Reader) membrane potential assay and then assessed by the YFP-based functional assay. Integrated with a halide-sensitive fluorescent reporter, these CF cell models can be used for high-throughput drug screening, as demonstrated by a proof-of-concept study using Trikafta. These cell models have the potential to advance CFTR mutation-specific therapies thus addressing the unmet needs of CF patients with rare mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, Rice University, Houston, Texas 77030, USA.
- Institute of Biosciences and Technology, Texas A&M University, Houston, Texas, 77030, USA.
- Department of Bioengineering, Rice University, Houston, Texas 77030, USA. Electronic address: gang.bao@rice.edu.
Förderung
- Cancer Prevention and Research Institute of Texas
- Cystic Fibrosis Foundation
Zitieren
APA
Liu, A., Chokshi, M., Nguyen, N., Powell, R. T., Stephan, C. C., & Bao, G. (2024). Cystic fibrosis cell models for high-throughput analysis and drug screening. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.07.001
Vancouver
Liu A, Chokshi M, Nguyen N, Powell RT, Stephan CC, Bao G. Cystic fibrosis cell models for high-throughput analysis and drug screening. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.07.001
BibTeX
@article{Liu2024,
author = {Liu, Aidi and Chokshi, Mithil and Nguyen, Nghi and Powell, Reid T and Stephan, Clifford C and Bao, Gang},
title = {Cystic fibrosis cell models for high-throughput analysis and drug screening},
journal = {Journal of Cystic Fibrosis},
year = {2024},
doi = {10.1016/j.jcf.2024.07.001}
}
EUVIMED